U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C28H27NO4S.ClH
Molecular Weight 510.0463
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RALOXIFENE HYDROCHLORIDE

SMILES

C1CCN(CC1)CCOc2ccc(cc2)C(=O)c3c4ccc(cc4sc3-c5ccc(cc5)O)O.Cl

InChI

InChIKey=BKXVVCILCIUCLG-UHFFFAOYSA-N
InChI=1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H

HIDE SMILES / InChI

Molecular Formula C28H27NO4S
Molecular Weight 473.5854
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00481 | https://www.drugs.com/pro/raloxifene-hydrochloride-tablets.html | https://www.ncbi.nlm.nih.gov/pubmed/11836973 | http://reference.medscape.com/drug/evista-raloxifene-342794

Raloxifene (marketed as Evista by Eli Lilly and Company) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. Raloxifene binds to estrogen receptors, resulting in differential expression of multiple estrogen-regulated genes in different tissues. Raloxifene produces estrogen-like effects on bone, reducing resorption of bone and increasing bone mineral density in postmenopausal women, thus slowing the rate of bone loss. The maintenance of bone mass by raloxifene and estrogens is, in part, through the regulation of the gene-encoding transforming growth factor-β3 (TGF-β3), which is a bone matrix protein with antiosteoclastic properties. Raloxifene activates TGF-β3 through pathways that are estrogen receptor-mediated but involve DNA sequences distinct from the estrogen response element. The drug also binds to the estrogen receptor and acts as an estrogen agonist in preosteoclastic cells, which results in the inhibition of their proliferative capacity. This inhibition is thought to contribute to the drug's effect on bone resorption. Other mechanisms include the suppression of the activity of the bone-resorbing cytokine interleukin-6 promoter activity. Raloxifene also antagonizes the effects of estrogen on mammary tissue and blocks uterotrophic responses to estrogen. By competing with estrogens for the estrogen receptors in reproductive tissue, raloxifene prevents the transcriptional activation of genes containing the estrogen response element. As well, raloxifene inhibits the estradiol-dependent proliferation of MCF-7 human mammary tumor cells in vitro. The mechanism of action of raloxifene has not been fully determined, but evidence suggests that the drug's tissue-specific estrogen agonist or antagonist activity is related to the structural differences between the raloxifene-estrogen receptor complex (specifically the surface topography of AF-2) and the estrogen-estrogen receptor complex. Also, the existence of at least 2 estrogen receptors (ERα, ERβ) may contribute to the tissue specificity of raloxifene. Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density. For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate. Common adverse events considered to be drug-related were hot flashes and leg cramps.

CNS Activity

Curator's Comment:: The penetration of raloxifene in blood–brain barrier protected regions is low and may render the detection of any brain effect difficult at the dosage currently used in practice

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
22.0 nM [EC50]
260.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
EVISTA

Approved Use

EVISTA® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. (1.1) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. (1.2) Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. (1.3) Important Limitations: EVISTA is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer. (1.3) 1.1 Treatment and Prevention of Osteoporosis in Postmenopausal Women EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see Clinical Studies (14.1, 14.2)

Launch Date

8.816256E11
Primary
EVISTA

Approved Use

EVISTA® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. (1.1) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. (1.2) Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. (1.3) Important Limitations: EVISTA is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer. (1.3) 1.1 Treatment and Prevention of Osteoporosis in Postmenopausal Women EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see Clinical Studies (14.1, 14.2)

Launch Date

8.816256E11
Primary
EVISTA

Approved Use

EVISTA® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. (1.1) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. (1.2) Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. (1.3) Important Limitations: EVISTA is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer. (1.3) 1.1 Treatment and Prevention of Osteoporosis in Postmenopausal Women EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see Clinical Studies (14.1, 14.2)

Launch Date

8.816256E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.5 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RALOXIFENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
27.2 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RALOXIFENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
27.7 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RALOXIFENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
180 mg 1 times / day single, oral
Studied dose
Dose: 180 mg, 1 times / day
Route: oral
Route: single
Dose: 180 mg, 1 times / day
Sources:
healthy, 18 months
n = 2
Health Status: healthy
Age Group: 18 months
Population Size: 2
Sources:
Other AEs: Ataxia, Dizziness...
Other AEs:
Ataxia
Dizziness
Vomiting
Rash
Diarrhea
Tremor
Flushing
Alkaline phosphatase increased
Sources:
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, Mean age 53.2 years
n = 63
Health Status: healthy
Age Group: Mean age 53.2 years
Sex: F
Population Size: 63
Sources:
Other AEs: Hot flashes...
Other AEs:
Hot flashes
Sources:
60 mg 1 times / day multiple, oral
Recommended
unhealthy, Mean age 68 years
n = 10101
Other AEs: Deep vein thrombosis, Pulmonary embolism...
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Mean age 68 years
n = 10101
Health Status: unhealthy
Age Group: Mean age 68 years
Sex: F
Population Size: 10101
Sources:
Disc. AE: Vomiting, Nausea...
AEs leading to
discontinuation/dose reduction:
Vomiting (0.3%)
Nausea (0.6%)
Oedema (0.6%)
Muscle spasms (0.7%)
Muscle related signs and symptoms NEC (1.6%)
Headache (0.3%)
Paralysis (0.1%)
Hot flush (1.4%)
Peripheral vascular disorder (1.6%)
Sources:
180 mg multiple, oral
Studied dose
Dose: 180 mg
Route: oral
Route: multiple
Dose: 180 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Other AEs: Leg cramps, Dizziness...
1.5 g 1 times / day single, oral
Studied dose
Dose: 1.5 g, 1 times / day
Route: oral
Route: single
Dose: 1.5 g, 1 times / day
Sources:
unhealthy
AEs

AEs

AESignificanceDosePopulation
Alkaline phosphatase increased
180 mg 1 times / day single, oral
Studied dose
Dose: 180 mg, 1 times / day
Route: oral
Route: single
Dose: 180 mg, 1 times / day
Sources:
healthy, 18 months
n = 2
Health Status: healthy
Age Group: 18 months
Population Size: 2
Sources:
Ataxia
180 mg 1 times / day single, oral
Studied dose
Dose: 180 mg, 1 times / day
Route: oral
Route: single
Dose: 180 mg, 1 times / day
Sources:
healthy, 18 months
n = 2
Health Status: healthy
Age Group: 18 months
Population Size: 2
Sources:
Diarrhea
180 mg 1 times / day single, oral
Studied dose
Dose: 180 mg, 1 times / day
Route: oral
Route: single
Dose: 180 mg, 1 times / day
Sources:
healthy, 18 months
n = 2
Health Status: healthy
Age Group: 18 months
Population Size: 2
Sources:
Dizziness
180 mg 1 times / day single, oral
Studied dose
Dose: 180 mg, 1 times / day
Route: oral
Route: single
Dose: 180 mg, 1 times / day
Sources:
healthy, 18 months
n = 2
Health Status: healthy
Age Group: 18 months
Population Size: 2
Sources:
Flushing
180 mg 1 times / day single, oral
Studied dose
Dose: 180 mg, 1 times / day
Route: oral
Route: single
Dose: 180 mg, 1 times / day
Sources:
healthy, 18 months
n = 2
Health Status: healthy
Age Group: 18 months
Population Size: 2
Sources:
Rash
180 mg 1 times / day single, oral
Studied dose
Dose: 180 mg, 1 times / day
Route: oral
Route: single
Dose: 180 mg, 1 times / day
Sources:
healthy, 18 months
n = 2
Health Status: healthy
Age Group: 18 months
Population Size: 2
Sources:
Tremor
180 mg 1 times / day single, oral
Studied dose
Dose: 180 mg, 1 times / day
Route: oral
Route: single
Dose: 180 mg, 1 times / day
Sources:
healthy, 18 months
n = 2
Health Status: healthy
Age Group: 18 months
Population Size: 2
Sources:
Vomiting
180 mg 1 times / day single, oral
Studied dose
Dose: 180 mg, 1 times / day
Route: oral
Route: single
Dose: 180 mg, 1 times / day
Sources:
healthy, 18 months
n = 2
Health Status: healthy
Age Group: 18 months
Population Size: 2
Sources:
Hot flashes
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, Mean age 53.2 years
n = 63
Health Status: healthy
Age Group: Mean age 53.2 years
Sex: F
Population Size: 63
Sources:
Deep vein thrombosis
60 mg 1 times / day multiple, oral
Recommended
unhealthy, Mean age 68 years
n = 10101
Pulmonary embolism
60 mg 1 times / day multiple, oral
Recommended
unhealthy, Mean age 68 years
n = 10101
Stroke
60 mg 1 times / day multiple, oral
Recommended
unhealthy, Mean age 68 years
n = 10101
Paralysis 0.1%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Mean age 68 years
n = 10101
Health Status: unhealthy
Age Group: Mean age 68 years
Sex: F
Population Size: 10101
Sources:
Headache 0.3%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Mean age 68 years
n = 10101
Health Status: unhealthy
Age Group: Mean age 68 years
Sex: F
Population Size: 10101
Sources:
Vomiting 0.3%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Mean age 68 years
n = 10101
Health Status: unhealthy
Age Group: Mean age 68 years
Sex: F
Population Size: 10101
Sources:
Nausea 0.6%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Mean age 68 years
n = 10101
Health Status: unhealthy
Age Group: Mean age 68 years
Sex: F
Population Size: 10101
Sources:
Oedema 0.6%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Mean age 68 years
n = 10101
Health Status: unhealthy
Age Group: Mean age 68 years
Sex: F
Population Size: 10101
Sources:
Muscle spasms 0.7%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Mean age 68 years
n = 10101
Health Status: unhealthy
Age Group: Mean age 68 years
Sex: F
Population Size: 10101
Sources:
Hot flush 1.4%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Mean age 68 years
n = 10101
Health Status: unhealthy
Age Group: Mean age 68 years
Sex: F
Population Size: 10101
Sources:
Muscle related signs and symptoms NEC 1.6%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Mean age 68 years
n = 10101
Health Status: unhealthy
Age Group: Mean age 68 years
Sex: F
Population Size: 10101
Sources:
Peripheral vascular disorder 1.6%
Disc. AE
60 mg 1 times / day multiple, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy, Mean age 68 years
n = 10101
Health Status: unhealthy
Age Group: Mean age 68 years
Sex: F
Population Size: 10101
Sources:
Dizziness
180 mg multiple, oral
Studied dose
Dose: 180 mg
Route: oral
Route: multiple
Dose: 180 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Leg cramps
180 mg multiple, oral
Studied dose
Dose: 180 mg
Route: oral
Route: multiple
Dose: 180 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 2.4 uM]
yes [IC50 3.7 uM]
yes [IC50 4.8 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
yes [Km 0.33 uM]
yes
yes
yes
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
2000 Dec
Initiation of osteoporosis treatment after bone mineral density testing.
2001
Alendronate: an update of its use in osteoporosis.
2001
Chemoprevention of breast cancer with fenretinide.
2001
In silico discovery of novel retinoic acid receptor agonist structures.
2001
[Modern approaches to hormone therapy of breast cancer as a reflection of pathogenesis of the disease].
2001
Raloxifene.
2001
[An alternative to postmenopausal Hormone Replacement Therapy? Selective Estrogens Receptors Modulators (SERMs)].
2001 Apr
Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients.
2001 Apr
Raloxifene fails to slow cognitive decline in older women.
2001 Apr 21
[SERM--selective estrogen receptor modulators].
2001 Apr 9
Bone builders: preventing and treating osteoporosis.
2001 Aug
Familiar drugs may prevent cancer.
2001 Aug
Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain.
2001 Aug
Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.
2001 Aug
An update on glucocorticoid-induced osteoporosis.
2001 Feb
Treatment of osteoporosis with bisphosphonates.
2001 Feb
Paradoxical interactions among estrogen receptors, estrogens and SERMS: mutual annihilation and synergy.
2001 Jan-Mar
Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351.
2001 Jan-Mar
Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women.
2001 Jul
Raloxifene effect on frequency of surgery for pelvic floor relaxation.
2001 Jul
Rheumatology: 15. Osteoporosis.
2001 Jul 10
Tamoxifen and contralateral breast cancer: the other side.
2001 Jul 4
Estradiol regulates monocyte chemotactic protein-1 in human coronary artery smooth muscle cells: a mechanism for its antiatherogenic effect.
2001 Jul-Aug
Tamoxifen, screening and new oestrogen receptor modulators.
2001 Jun
Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells.
2001 Jun
Medication update.
2001 Jun
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference.
2001 Jun
Tibolone and its effects on bone: a review.
2001 Jun
Osteoporosis.
2001 Jun
Tamoxifen to raloxifene and beyond.
2001 Jun
Breast cancer chemoprevention: current status and future directions.
2001 Jun
Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
2001 Jun
Effect of physicians opinion on patients' choice of treatment.
2001 Jun
Oestrogenic effects of neonatal administration of raloxifene on hypothalamic-pituitary-gonadal axis in male and female rats.
2001 Jun
Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
2001 Jun 12
Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
2001 Jun 15
SERMs and cardiovascular disease in women. How do these agents affect risk?
2001 Mar
Therapy for osteoporosis.
2001 Mar
Osteoporosis: part II. Nonpharmacologic and pharmacologic treatment.
2001 Mar 15
Prevention and treatment of osteoporosis.
2001 Mar-Apr
Effects of the selective oestrogen receptor modulator-raloxifene-on calcium and PTH secretory dynamics in women with osteoporosis.
2001 May
Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites.
2001 May
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.
2001 May
Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
2001 May 1
Flexible alignment of small molecules.
2001 May 10
Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats.
2001 May 4
Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism.
2001 May 4
From adjuvant therapy to breast cancer prevention: BCPT and STAR.
2001 May-Jun
Cardiovascular effects of raloxifene hydrochloride.
2001 Spring
Patents

Sample Use Guides

60 mg tablet orally once daily
Route of Administration: Oral
MCF-7 cells were obtained from the ATCC and grown in Growth Medium (GM). The cells are grown to 80% confluency and trypsinized and washed to remove phenol red, then plated at 10,000 cells/well in Starve Medium (SM). After 2 days, the medium is removed from the cells and either fresh SM or SM plus Raloxifene is added (100 mL total volume). The next day the bDNA assay is started by adding Capture Hybridization Buffer to each capture well of the bDNA plate (all solutions supplied with QuantiGene kit). Subsequently, medium is removed from the 96-well plate containing cells and then the solution of lysis buffer and oligomers (designed by ProbeDesigner 1.0 for the gene of interest) is added to the 96-well plate (100 mL/well). The cell and lysis/ oligomer mixture is incubated for 15 min at 53 C and then vortexed for 1 min. The lysate is then transferred to the bDNA capture plate and mixed. The plate is then sealed and incubated at 53 C for 16 h. The next day, the plate is cooled for 10 min at room temperature and the Amplifier Reagent mixture is prepared. The wells are then washed twice with 200 mkL of Wash Solution A. Amplifier Reagent is added (50 mkL/well) and the plate is sealed again and incubated at 53 C for 30 min. The plate is then cooled for 10 min at room temperature (rt) and the Label Probe Reagent is prepared. The plate is washed twice with 200 mkL of Wash Solution A and 50 mkL/well of Label Probe Reagent is added. The plate is sealed and incubated at 53 C for 15 min. The plate is cooled for 10 min at rt and the Substrate Mixture is prepared. The plate is again washed twice with 200 mkL Wash Solution A and then twice with Wash Solution D. The Substrate Mixture is then added (50 mkL) and the plate is sealed. The plate is incubated at 37 C for 30 min and then read on the Quantiplex luminometer. Raloxifene is used as a positive control in this assay, and behaves as a full antagonist of estrogen-induced pS2 expression.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:02:09 UTC 2021
Edited
by admin
on Fri Jun 25 21:02:09 UTC 2021
Record UNII
4F86W47BR6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RALOXIFENE HYDROCHLORIDE
EMA EPAR   EP   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
RALOXIFENE HYDROCHLORIDE [JAN]
Common Name English
NSC-706725
Code English
6-HYDROXY-2-(P-HYDROXYPHENYL)BENZO(.BETA.)THIEN-3-YL-P-(2-PIPERIDINOETHOXY)PHENYL KETONE, HYDROCHLORIDE
Common Name English
RALOXIFENE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
RALOXIFENE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
METHANONE, (6-HYDROXY-2-(4-HYDROXYPHENYL)BENZO(.BETA.)THIEN-3-YL)(4-(2-(1-PIPERIDINYL)ETHOXY)PHENYL)-, HYDROCHLORIDE
Common Name English
RALOXIFENE HCL
Common Name English
RALOXIFENE HYDROCHLORIDE [USAN]
Common Name English
RALOXIFENE HYDROCHLORIDE [VANDF]
Common Name English
RALOXIFENE HYDROCHLORIDE [MI]
Common Name English
RALOXIFENE TEVA
Brand Name English
RALOXIFENE HYDROCHLORIDE [MART.]
Common Name English
RALOXIFENE HYDROCHLORIDE [WHO-DD]
Common Name English
OPTRUMA
Brand Name English
LY156758
Code English
RALOXIFENE HYDROCHLORIDE [USP]
Common Name English
EVISTA
Common Name English
LY-156758
Code English
RALOXIFENE HYDROCHLORIDE [EMA EPAR]
Common Name English
RALOXIFENE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
RALOXIFENE HYDROCHLORIDE [USP-RS]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS EVISTA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
EMA ASSESSMENT REPORTS OPTRUMA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
FDA ORPHAN DRUG 309910
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
EU-Orphan Drug EU/3/10/730
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
EMA ASSESSMENT REPORTS RALOXIFENE TEVA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
NCI_THESAURUS C1821
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL81
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY
PUBCHEM
54900
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY
CAS
82640-04-8
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY
DRUG BANK
DBSALT000272
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY
EPA CompTox
82640-04-8
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY
EVMPD
SUB12568MIG
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY
USP_CATALOG
1598201
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY USP-RS
RXCUI
166551
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M9485
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C1762
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY
FDA UNII
4F86W47BR6
Created by admin on Fri Jun 25 21:02:09 UTC 2021 , Edited by admin on Fri Jun 25 21:02:09 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
IMPURITY -> PARENT
RALOXIFENE HYDROCHLORIDE IMPURITY B [EP] AMOUNT NOT SPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
RALOXIFENE HYDROCHLORIDE IMPURITY C [EP] AMOUNT NOT SPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY